Clinical trials: Cytomegalovirus
Acquired Immunodeficiency Syndrome, Lung Diseases
Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2)
To determine the prevalence and natural history of pulmonary and cardiac complications associated with HIV infection in utero, in infancy, and during early childhood.
- Conditions
- Acquired Immunodeficiency Syndrome, Lung Diseases, Cardiovascular Diseases, Heart Diseases
- Trial name
- NCT00005274
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cytomegalovirus Infections, HIV Infections
A Study of Lobucavir in Patients With AIDS
The purpose of this study is to see if lobucavir is a safe and effective treatment for cytomegalovirus in patients with AIDS.
- Trial name
- NCT00002352
- Testing
- Lobucavir
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Cytomegalovirus Infections
A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)
AVX601, a bivalent alphavirus replicon vaccine expressing three CMV proteins (gB, pp65 and IE1) is a candidate vaccine against cytomegalovirus (CMV).
- Trial name
- CMV (NCT00439803)
- Testing
- AVX601
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
Cytomegalovirus Retinitis, HIV Infections
The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes
To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV ) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are otherwise ineligible for ISIS Pharmaceuticals'…
- Trial name
- NCT00002356
- Testing
- Fomivirsen sodium
- Where
- 25 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Infections
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
This study will evaluate the safety, tolerability, and immunogenicity of various doses, formulations, and routes of administration of Human Cytomegalovirus (HCMV) vaccine V160 administered in a 3-dose regimen in healthy adults.
- Trial name
- NCT01986010
- Testing
- V160 Low Dose IM, V160 Medium Dose IM, V160 High Dose IM
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus (CMV)
Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies
This is an open-label, single arm, multicenter study to evaluate the feasibility of maribavir treatment in multiple myeloma and lymphoma patients undergoing bispecific antibody treatment and experiencing treatment emergent CMV…
- Trial name
- MALMBA (NCT07014319)
- Testing
- Maribavir
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
HIV Infections
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
Original design: The study's purpose is to compare the effects of zidovudine (AZT) alone to the combination of AZT and acyclovir (ACV) to determine if AZT/ACV is associated with a lower death rate and fewer AIDS related…
- Trial name
- NCT00000712
- Testing
- Zidovudine, Acyclovir
- Where
- 8 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV or EBV in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
- Trial name
- NCT04364178
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jessie L. Alexander, MD
Glioblastoma, Glioblastoma Multiforme
Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Newly diagnosed glioblastoma (GBM) patients with complete or partial surgical resection who were CMV seropositive patients were eligible to enroll on this trial.
- Trial name
- PERFORMANCE (NCT02864368)
- Testing
- 5-day TMZ, 21-day TMZ, PEP-CMV: Component A
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Eric Thompson, M.D.
Allogeneic Hematopoietic Stem Cell Transplantation, CMV Infection
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.
- Trial name
- NCT05089838
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xiao-Jun Huang
Epstein-Barr Virus Infection, Cytomegalovirus Infections
TETRAVI Expanded Access Program
This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the…
- Conditions
- Epstein-Barr Virus Infection, Cytomegalovirus Infections, Adenovirus Infection, BK Virus Infection
- Trial name
- NCT07104591
- Testing
- HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)
- Sponsor
- Baylor College of Medicine
Glioblastoma Multiforme, Astrocytoma, Grade IV
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
The goal of this clinical trial is to test a combined therapy approach (allogeneic cytomegalovirus [CMV]-specific T cells and pembrolizumab) in patients with brain cancer.
- Trial name
- TCaP (NCT06157541)
- Testing
- Allogeneic cytomegalovirus-specific T cells, Pembrolizumab
- Where
- 4 sites in Australia
- Volunteers
- 58 people
- Sponsor
- Queensland Institute of Medical Research
Cytomegalovirus (CMV)
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe [EU] and Canada [CAN]). Data will be collected retrospectively from medical charts.
- Trial name
- NCT05571137
- Where
- 11 sites in Austria, Belgium and 5 more
- Volunteers
- 118 people
- Sponsor
- Takeda
Cytomegalovirus Infection
Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
The objectives of this study were: 1. To demonstrate the efficacy/safety of a short therapeutic strategy of treatment of CMV infection/disease in SOT patients (kidney, liver and heart recipients) based on 21 days of treatment. 2.
- Trial name
- NCT00730769
- Testing
- Single arm (ganciclovir and valganciclovir)
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Salvador Gil-Vernet
HIV Infections, Acquired Immunodeficiency Syndrome
Longitudinal Study of Ocular Complications of AIDS (LSOCA)
To monitor trends over time, in the incidence of CMV retinitis and other ocular complications of AIDS To determine the effect of highly active anti-retroviral therapy (HAART)-induced immune status on the risk of developing CMV…
- Conditions
- HIV Infections, Acquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis
- Trial name
- LSOCA (NCT00000168)
- Where
- 19 sites in United States
- Volunteers
- 2,392 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cytomegalovirus (CMV) Infection, Kidney Transplantation
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative…
- Trial name
- NCT03629080
- Testing
- HB-101 vaccine
- Where
- 25 sites in United States, Denmark and 4 more
- Volunteers
- 83 people
- Sponsor
- Hookipa Biotech GmbH
Cytomegalovirus Infections
gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females
The purpose of this research study is to test the safety of and the body's response to an experimental cytomegalovirus (CMV) vaccine (called gB/MF59 vaccine).
- Trial name
- NCT00133497
- Testing
- MF-59, CMV gB vaccine
- Where
- 5 sites in United States
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Failure Chronic Requiring Dialysis
Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients
Cell-mediated immunity (CMI) and in particular T cells play a critical role in the rejection of transplanted organs. Thus, in transplant recipients a life-long and individualized immunosuppressive medication is required to avoid…
- Trial name
- NCT02630537
- Volunteers
- 133 people
- Sponsor
- Lophius Biosciences GmbH
Cytomegalovirus Infections
Immune Response to Cytomegalovirus
This study will evaluate immune responses against cytomegalovirus (CMV). About 80 percent of adults have been exposed to this virus. CMV typically remains dormant (inactive) in the body, causing no problems.
- Trial name
- NCT00034437
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cytomegalovirus Infection
Alternate Donor Study of Pre-Emptive Cellular Therapy
The purpose of this study is to evaluate the potential clinical benefit of pre-emptive cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT)…
- Trial name
- CMV-ACE/ASPECT (NCT01220895)
- Testing
- CMV-specific T-cells, single infusion following single positive CMV PCR result
- Where
- 9 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- Cell Medica Ltd